Camelid single-domain antibody directed against amyloid beta and methods for producing conjugates thereof
US9738712B2 · kind B2 · utility
2Cited by
0References
32Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 13, 2014 |
| Grant date | Aug 22, 2017 |
| Priority date | — |
| Expiry date | Nov 13, 2034 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to variable domain of a camelid heavy-chain antibodies directed to amyloid β and conjugates thereof. The present invention also relates to the use of these antibody conjugates for treating or diagnosing disorders mediated by amyloid β deposits.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.